Analyst Ratings For ArQule, Inc. (NASDAQ:ARQL)
Today, Royal Bank of Canada initiated coverage on ArQule, Inc. (NASDAQ:ARQL) with a Outperform with a price target of $9.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on ArQule, Inc. (NASDAQ:ARQL) is Buy with a consensus target price of $7.80 per share, a potential 39.04% upside.
Some recent analyst ratings include
- 4/11/2019-ArQule, Inc. (NASDAQ:ARQL) has coverage initiated with a Outperform rating and $9.00 price target
- 4/5/2018-ArQule, Inc. (NASDAQ:ARQL) gets upgraded to Outperform by Leerink Swann
- On 7/13/2018 Ran Nussbaum, Director, bought 181,818 with an average share price of $5.50 per share and the total transaction amounting to $999,999.00.
- On 5/30/2018 Value Fund L P Biotechnology, Insider, sold 1,035,939 with an average share price of $5.00 per share and the total transaction amounting to $5,179,695.00.
- On 5/18/2018 Paolo Pucci, CEO, bought 15,000 with an average share price of $3.39 per share and the total transaction amounting to $50,850.00.
- On 5/18/2018 Ran Nussbaum, Director, bought 8,611 with an average share price of $3.29 per share and the total transaction amounting to $28,330.19.
- On 5/14/2018 Patrick J Zenner, Director, bought 8,446 with an average share price of $2.96 per share and the total transaction amounting to $25,000.16.
- On 5/10/2018 Paolo Pucci, CEO, bought 1,300 with an average share price of $2.64 per share and the total transaction amounting to $3,432.00.
- On 5/10/2018 Ronald M Lindsay, Director, bought 23,900 with an average share price of $2.67 per share and the total transaction amounting to $63,813.00.
About ArQule, Inc. (NASDAQ:ARQL)
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Recent Trading Activity for ArQule, Inc. (NASDAQ:ARQL)
Shares of ArQule, Inc. closed the previous trading session at 5,61 −0,050 0,88 % with 6 shares trading hands.